KSQ Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
103
- Latest Deal Type
-
Later Stage VC
- Investors
-
2
KSQ General Information
Description
Developer of transformative medicines designed to systematically pinpoint the optimal nodal targets of disease with precision. The company's industrialized functional genomics engine utilizes a suite of tools that identify novel pathways and targets involved in oncology and immuno-oncology, enabling doctors to uncover novel drug targets, and mechanisms for drug efficacy and identify transformative single-agent and combination therapies to benefit patients.
Contact Information
Website
www.ksqtx.comCorporate Office
- 4 Maguire Road
- Lexington, MA 02421
- United States
Corporate Office
- 4 Maguire Road
- Lexington, MA 02421
- United States
KSQ Timeline
KSQ Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 01-Jul-2026 | Completed | Clinical Trials - Phase 1 | |||
| 8. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 7. Mezzanine | 31-Mar-2025 | Completed | Clinical Trials - Phase 1 | |||
| 6. Mezzanine | 26-Apr-2022 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series D) | 23-Dec-2021 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series C) | 28-Sep-2018 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series B) | 02-Oct-2017 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 16-Mar-2017 | $10M | $25.5M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | 20-Oct-2015 | $15.5M | $15.5M | Completed | Startup |
KSQ Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 22,566,371 | $0.000100 | $2.26 | $2.26 | 1x | $2.26 | 19.56% | |
| Series A | 25,560,000 | $0.000100 | $1 | $1 | 1x | $1 | 22.15% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
KSQ Comparisons
Industry
Financing
Details
KSQ Competitors (38)
One of KSQ’s 38 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Strand (Biotechnology) | Formerly VC-backed | Bangalore, India | ||||
| Partek | Corporate Backed or Acquired | Chesterfield, MO | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA |
KSQ Patents
KSQ Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026107320-A1 | Gene-regulating compositions and methods for improved immunotherapy | Pending | 15-Nov-2024 | ||
| WO-2025106513-A1 | Methods for producing edited tumor infiltrating lymphocytes | Inactive | 13-Nov-2023 | ||
| WO-2025106513-A8 | Methods for producing edited tumor infiltrating lymphocytes | Inactive | 13-Nov-2023 | ||
| AU-2023347293-A1 | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and parp1-selective inhibitors | Pending | 23-Sep-2022 | ||
| EP-4590297-A2 | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and parp1-selective inhibitors | Pending | 23-Sep-2022 | A61K31/519 |
KSQ Signals
KSQ Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| LG Technology Ventures | Corporate Venture Capital | Minority | ||
| UCSF Innovation Ventures | Venture Capital | Minority |
KSQ FAQs
-
When was KSQ founded?
KSQ was founded in 2015.
-
Where is KSQ headquartered?
KSQ is headquartered in Lexington, MA.
-
What is the size of KSQ?
KSQ has 103 total employees.
-
What industry is KSQ in?
KSQ’s primary industry is Biotechnology.
-
Is KSQ a private or public company?
KSQ is a Private company.
-
What is KSQ’s current revenue?
The current revenue for KSQ is .
-
How much funding has KSQ raised over time?
KSQ has raised $324M.
-
Who are KSQ’s investors?
LG Technology Ventures and UCSF Innovation Ventures have invested in KSQ.
-
Who are KSQ’s competitors?
Regenxbio, Strand (Biotechnology), Partek, Adaptimmune Therapeutics, and Genetix Biotherapeutics are some of the 38 competitors of KSQ.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process